JSSc: Juvenile Systemic Sclerosis, a Retrospective Epidemiological Study on a French Cohort

Sponsor

University Hospital, Strasbourg, France (Other)

Overall Status

Recruiting

CT.gov ID

NCT06019234

Collaborator

(none)

Enrollment

Location

19.1

Anticipated Duration (Months)

1.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Scleroderma is an inflammatory attack of the vessels leading to localized or multisystemic sclerosis. It is a rare autoimmune pathology in pediatrics.

The incidence in pediatrics is very low (about 4 per million according to an American) and therefore the data on the pathology very poor, especially on the therapeutic level.

The proposed immunosuppressive treatments are extrapolated from data in adults. The evolution of connectivity does not seem quite identical to the evolution of adult scleroderma, adaptation of treatments seems judicious. However, data on the evolution under therapy in children are still poor.

Complications related to the pathology, iatrogeny and diagnostic delay are the first causes of mortality from this pathology and deserve to be studied and if possible avoided.

The main hypothesis of the research being to bring together the experiences of the various reference and competence centers in France concerning the clinical presentation, management and follow-up of children with systemic sclerosis.

Condition or Disease	Intervention/Treatment	Phase
Juvenile Systemic Sclerosis

Study Design

Study Type:

Observational

Anticipated Enrollment :

30 participants

Observational Model:

Case-Only

Time Perspective:

Retrospective

Official Title:

Uvenile Systemic Sclerosis, a Retrospective Epidemiological Study on a French Cohort

Actual Study Start Date :

Mar 3, 2023

Anticipated Primary Completion Date :

Oct 3, 2024

Anticipated Study Completion Date :

Oct 3, 2024

Outcome Measures

Primary Outcome Measures

Description of the various treatments for juvenile systemic sclerosis in France [Files analysed retrospectively from January 01, 2012 to June 30, 2022 will be examined]
The aim of this study is to bring together the experiences of the various reference and competence centers in France concerning the clinical presentation, management and follow-up of children with systemic sclerosis.

Eligibility Criteria

Criteria

Ages Eligible for Study:

1 Year to 17 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion criteria:

Minor subject (<18 years old)
Diagnosis of systemic sclerosis between 01/01/2012 and 30/06/2022.
Subject (and/or his parental authority) who has not expressed, after being informed, his opposition to the reuse of his data for the purposes of this research.